Lurasidone /lɜrəsɪduː/[citation needed] (trade name Latuda) is a new atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the USA. In the USA it is also approved for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults when used alone or in combination with lithium or valproate.
This page contains content from the copyrighted Wikipedia article "Lurasidone"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
